Filtered By:
Source: Thrombosis and Haemostasis
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 186 results found since Jan 2013.

Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke
Thromb Haemost. 2023 Mar;123(3):366-376. doi: 10.1055/s-0042-1760257. Epub 2023 Mar 2.ABSTRACTINTRODUCTION: Atrial fibrillation (AF) is a common cause of stroke. Timely diagnosis of AF and treatment with oral anticoagulation (OAC) can prevent up to two-thirds of AF-related strokes. Ambulatory electrocardiographic (ECG) monitoring can identify undiagnosed AF in at-risk individuals, but the impact of population-based ECG screening on stroke is uncertain, as ongoing and published randomized controlled trials (RCTs) have generally been underpowered for stroke.METHODS AND ANALYSIS: The AF-SCREEN Collaboration, with support from...
Source: Thrombosis and Haemostasis - March 2, 2023 Category: Hematology Authors: AF SCREEN and AFFECT-EU Collaborators Source Type: research

Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation.
PMID: 24477628 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 30, 2014 Category: Hematology Authors: Lane DA, Lip GY Tags: Thromb Haemost Source Type: research

Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation.
The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF. PMID: 24573511 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 27, 2014 Category: Hematology Authors: Hylek EM, Ko D, Cove CL Tags: Thromb Haemost Source Type: research

Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
CONCLUSIONS: In a warfarin-treated trial cohort of AF patients, both CHA2DS2-VASc and GARFIELD-AF Stroke scores were associated with adjudicated TE events, with modest predictive capacity. Simpler CHA2DS2-VASc score improved discriminatory capacity compared to more complex GARFIELD-AF score, demonstrating improved clinical usefulness and net clinical benefit. PMID: 33296920 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 9, 2020 Category: Hematology Authors: Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GY Tags: Thromb Haemost Source Type: research

Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study
CONCLUSIONS: Although the non-randomized nature of the study is prone to bias, anticoagulation with VKA was not associated with decreased thromboembolic risk, but associated with increased risk of major bleeding and may be net-harmful to patients with AF on HD.PMID:34418291 | DOI:10.1111/jth.15508
Source: Thrombosis and Haemostasis - August 21, 2021 Category: Hematology Authors: Oliver K önigsbrügge Hannah Meisel Aljoscha Beyer Sabine Schmaldienst Renate Klauser-Braun Matthias Lorenz Martin Auinger Josef Kletzmayr Manfred Hecking Wolfgang C Winkelmayer Irene Lang Ingrid Pabinger Marcus S äemann Cihan Ay Source Type: research

Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification?
Thromb Haemost. 2022 Jan 19. doi: 10.1055/a-1745-2083. Online ahead of print.ABSTRACTPatients with heart failure (HF) in sinus rhythm (SR) experience an increased incidence of thromboembolic events including stroke. Among patients with HF, high-quality evidence supports the use of oral anticoagulation when atrial fibrillation (AF) is present, but the benefit of anticoagulation in SR in absence of other known indications for anticoagulation is unclear. In four randomized controlled trials (RCTs), warfarin did not improve a composite of clinical outcomes compared with aspirin or placebo in patients with HF with reduced eject...
Source: Thrombosis and Haemostasis - January 19, 2022 Category: Hematology Authors: Angelica Rivas Mandy N Lauw Renate Bonin-Schnabel Mark Crowther Harriette Van Spall Source Type: research

Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study
CONCLUSION: FXIa present in circulating blood is associated with increased risk of ischemic stroke and cardiovascular death in anticoagulated AF patients during long-term follow-up. FXIa inhibition could be useful in cardiovascular prevention in AF beyond the current oral anticoagulation.PMID:35158400 | DOI:10.1055/s-0042-1742366
Source: Thrombosis and Haemostasis - February 14, 2022 Category: Hematology Authors: Micha ł Tomasz Ząbczyk Maksymilian Hanarz Krzysztof P Malinowski El żbieta Pociask Saulius Butenas Grzegorz Gajos Anetta Undas Source Type: research

New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Abstract Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials. The first three have been approved, while edoxaban is awaiting regulatory approval. Several guidelines have endorsed the approved new oral anticoagulants over warfarin because of their favourable risk-benefit ratio, low propensity for food and drug interactions, and lack of requirement for routine coagulation monitoring. In this invited review, we summarise ...
Source: Thrombosis and Haemostasis - February 20, 2014 Category: Hematology Authors: Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS Tags: Thromb Haemost Source Type: research

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: comment.
This article is protected by copyright. All rights reserved. PMID: 27431450 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 18, 2016 Category: Hematology Authors: Mantha S, Moll S, Hilden P, Devlin S, Rose A Tags: J Thromb Haemost Source Type: research

Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
CONCLUSION:  The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice. PMID: 32668484 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 14, 2020 Category: Hematology Authors: de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, Ginsberg JS, Kruger PC, Chan NC Tags: Thromb Haemost Source Type: research

The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation.
Abstract Atrial fibrillation (AF) is a complex condition requiring holistic management with multiple treatment decisions about optimal thromboprophylaxis, symptom control (and prevention of AF progression), and identification and management of concomitant cardiovascular risk factors and comorbidity. Sometimes the information needed for treatment decisions is incomplete, as available classifications of AF mostly address a single domain of AF (or patient)-related characteristics. The most widely used classification of AF based on AF episode duration and temporal patterns (that is, the classification to first-diagnos...
Source: Thrombosis and Haemostasis - August 23, 2020 Category: Hematology Authors: Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC, Heidbuchel H, Hindricks G, Camm AJ Tags: Thromb Haemost Source Type: research

Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation
CONCLUSIONS: In AF patients with severe AIS, early OAC use before the guideline-recommended days appeared to increase the risk of bleeding events, although the OAC initiation time seemed not to affect the risk of serious vascular events. The optimal severity-specific timing for OAC initiation after AIS requires further evaluation.PMID:34649296 | DOI:10.1055/a-1669-4987
Source: Thrombosis and Haemostasis - October 14, 2021 Category: Hematology Authors: Po-Yin Chang Weiting Wang Wei-Lun Wu Hui-Chin Chang Chen-Huan Chen Yi-Wen Tsai Shih-Hwa Chiou Gregory Yh Lip Hao-Min Cheng Chern-En Chiang Source Type: research

Early rhythm control and the risks of ischaemic stroke, heart failure, mortality and adverse events when performed early ( & lt;3 months)
CONCLUSIONS: Early rhythm control, especially when performed earlier (<3months), was associated with a lower risk of adverse events than usual care among patients with early AF.PMID:35322396 | DOI:10.1055/a-1807-0336
Source: Thrombosis and Haemostasis - March 24, 2022 Category: Hematology Authors: Tze-Fan Chao Yi-Hsin Chan Chern-En Chiang Ta-Chuan Tuan Jo-Nan Liao Tzeng-Ji Chen Gregory Yh Lip Shih-Ann Chen Source Type: research